Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor
 

Summary: Experimental therapy of African trypanosomiasis with a
nanobody-conjugated human trypanolytic factor
Toya Nath Baral1, Stefan Magez1, Benoi^t Stijlemans1, Katja Conrath1, Benoit Vanhollebeke2, Etienne Pays2,
Serge Muyldermans1 & Patrick De Baetselier1
High systemic drug toxicity and increasing prevalence of drug
resistance hampers efficient treatment of human African
trypanosomiasis (HAT). Hence, development of new highly
specific trypanocidal drugs is necessary. Normal human serum
(NHS) contains apolipoprotein L-I (apoL-I), which lyses African
trypanosomes except resistant forms such as Trypanosoma
brucei rhodesiense1. T. b. rhodesiense expresses the apoL-I­
neutralizing serum resistance­associated (SRA) protein2,
endowing this parasite with the ability to infect humans and
cause HAT. A truncated apoL-I (Tr-apoL-I) has been engineered
by deleting its SRA-interacting domain, which makes it lytic for
T. b. rhodesiense1. Here, we conjugated Tr-apoL-I with a single-
domain antibody (nanobody) that efficiently targets conserved
cryptic epitopes of the variant surface glycoprotein (VSG)
of trypanosomes3 to generate a new manmade type of
immunotoxin with potential for trypanosomiasis therapy.

  

Source: Arnold, Jonathan - Nanoscale Science and Engineering Center & Department of Genetics, University of Georgia

 

Collections: Biotechnology